Pfizer rheumatoid arthritis drug meets primary endpoint
Pfizer has reported that a Phase III study (A3921046) of Tofacitinib, an investigational, novel, oral JAK inhibitor, being evaluated in moderate-to-severe rheumatoid arthritis (RA), met its primary endpoints.
In the study, Tofacitinib showed changes versus placebo in reducing signs and symptoms of RA; in improving physical function; and in reaching DAS28-4(ESR) <2.6 at six months.
The safety profile of Tofacitinib was consistent with previously seen results of clinical programme, and no new safety signal was identified.
The Phase III study evaluated the efficacy and safety of Tofacitinib doses 5mg and 10mg given twice daily compared to placebo in patients with moderately to severely active RA.
Related Insight
Suppliers Directory
ENNOV - Medical Device and Drug Development Compliance Specialists
ENNOV INC. (Ennov) provides Ennov5 "Business Suite Solutions" to enable companies to obtain and maintain regulatory compliance while focusing their attention on the business of maximizing profitability by leveraging computing technology.
Contract Research & Services > Clinical Trials > Suppliers
Clinical Trial Company - CRO Offering Project Management, Clinical Monitoring and Strategic Development Consultancy
The Clinical Trial Company (TCTC) is a full service clinical contract research organisation (CRO) and was formed in the UK in 2002. As a full service CRO, TCTC specialises in clinical studies for pharmaceutical, biotech and medical device companies.
Contract Research & Services > Clinical Trials > Suppliers
Haupt Pharma - Contract Development and Manufacturing, Clinical Trial Supplies, Regulatory Services, Packaging and Logistics
As one of Europe's largest pharmaceutical contract developers and manufacturers Haupt Pharma offers full service, which covers pharmaceutical development, materials procurement, commercial production, packaging and distribution.
Contract Research & Services > Clinical Trials > Suppliers
CCL Label - Global Healthcare and Pharmaceutical Packaging Solutions
CCL Label is a Global Manufacturer of Pharmaceutical and Healthcare packaging. With 20 healthcare sites globally, we offer the expertise, trained personnel and dedicated production capabilities to ensure that your pharmaceutical/healthcare labelling is accurate, secure and meets all FDA requirements and current Good Manufacturing Practices (GMP)
Contract Research & Services > Clinical Trials > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Clinical Trials Intelligence
Seamless Life Sciences Collaboration
Published by Brainloop
Contract Research & Services > Clinical Trials > White Papers
Why, When and How to Conduct 14C Human Studies
Published by SGS PBR
Contract Research & Services > Clinical Trials > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.